Patients on peritoneal dialysis but not on hemodialysis have elevated concentration and activity of thrombin-activatable fibrinolysis inhibitor

Thrombosis Research

Volumn 104, Issue 4, 2001, Pages 233-238

  Hryszko, Tomasz ^b   Ma, Jolanta ^a   Ma, Jacek S ^a   Brzósko, Szymon ^a   Myśliwiec, Michal ^a  

^a Department of Nephrology and Internal Medicine   (United States)

^b MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Cholesterol; Dialysis; Fibrinogen; TAFI; Triglycerides

Indexed keywords

ALBUMIN; CHOLESTEROL; FIBRINOGEN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORRELATION FUNCTION; DYSLIPIDEMIA; FEMALE; FIBRINOLYSIS; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RISK FACTOR;

ADULT; AGED; CARBOXYPEPTIDASE U; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CHOLESTEROL; FEMALE; FIBRINOGEN; HUMANS; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; RENAL DIALYSIS; RISK FACTORS; TRIGLYCERIDES;

EID: 0035891559     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(01)00364-4     Document Type: Article

References (17)

1. The triglyceride issue: A view from Framingham
2. Systematic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: Data from the BUPA study
3. Fibrinolytic activity, clotting factors, and long-term incidence of ischemic heart disease in the Northwick Park Heart study
4. Fibrinogen and risk of cardiovascular disease: The Framingham Study
5. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease
6. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor
7. Both cellular and soluble forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of thrombin-activable fibrinolysis inhibitor
8. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor
9. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation
10. An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model
11. Fibrinogen, coagulation factor VII, tissue plasminogen activator, plasminogen activator inhibitor-1 and lipid as cardiovascular risk factors in chronic hemodialysis and continuous ambulatory peritoneal dialysis patients
12. Lipids in CAPD: A review
13. Cardiovascular disease, fibrinogen and the acute phase response: Associations with lipids and blood pressure in patients with chronic renal disease
14. Thrombin-activatable fibrinolysis inhibitor and the risk for deep vein thrombosis
15. Plasma levels of TAFI are elevated in patient with unstable angina pectoris (UAP) compared to stable angina pectoris but show no relationship with outcome of UAP
16. Atherosclerosis and the coagulation system